ASH® 2025 Highlights: Presenter Vignette – Hanny Al-Samkari
Hanny Al-Samkari
MD
Harvard Medical School
LBA 2
Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment
This program has been made possible through unrestricted support from Astellas, Daiichi Sankyo, Eli Lilly and Merck.